This 2018 review explores the repositioning of ivermectin, traditionally an antiparasitic agent, as a novel anticancer drug. The article highlights ivermectin’s ability to target multiple molecular pathways critical to cancer cell survival and proliferation. Mechanistically, ivermectin inhibits P-glycoprotein to overcome drug resistance, acts on chloride ion channels to induce apoptosis,
